Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

被引：309

作者：

Abbas, Saman ^{[2
]}

Lugthart, Sanne ^{[2
]}

Kavelaars, Francois G. ^{[2
]}

Schelen, Anita ^{[2
]}

Koenders, Jasper E. ^{[2
]}

Zeilemaker, Annelieke ^{[2
]}

van Putten, Wim J. L. ^{[1
]}

Rijneveld, Anita W. ^{[2
]}

Lowenberg, Bob ^{[2
]}

Valk, Peter J. M. ^{[2
]}

机构：

[1] Erasmus MC, Dept Trials & Stat, NL-3015 GE Rotterdam ZH, Netherlands

[2] Erasmus MC, Dept Hematol, NL-3015 GE Rotterdam ZH, Netherlands

来源：

BLOOD | 2010年 / 116卷 / 12期

关键词：

ISOCITRATE-DEHYDROGENASE; 1; GLIOMAS;

D O I：

10.1182/blood-2009-11-250878

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) were recently demonstrated in acute myeloid leukemia (AML), but their prevalence and prognostic impact remain to be explored in large extensively characterized AML series, and also in various other hematologic malignancies. Here, we demonstrate in 893 newly diagnosed cases of AML mutations in the IDH1 (6%) and IDH2 (11%) genes. Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). In AML, IDH1 and IDH2 mutations are more common among AML with normal karyotype and NPM1(mutant) genotypes. IDH1 mutation status is an unfavorable prognostic factor as regards survival in a composite genotypic subset lacking FLT3(ITD) and NPM1(mutant). Thus, IDH1 and IDH2 mutations are common genetic aberrations in AML, and IDH1 mutations may carry prognostic value in distinct sub-types of AML. (Blood. 2010;116(12):2122-2126)

引用

页码：2122 / 2126

页数：5

共 14 条

[11] Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML):: association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance [J].

Verhaak, RGW ;

Goudswaard, CS ;

van Putten, W ;

Bijl, MA ;

Sanders, MA ;

Hugens, W ;

Uitterlinden, AG ;

Erpelinck, CAJ ;

Delwel, R ;

Löwenberg, B ;

Valk, PJM .

BLOOD, 2005, 106 (12) :3747-3754

[12] The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate [J].

Ward, Patrick S. ;

Patel, Jay ;

Wise, David R. ;

Abdel-Wahab, Omar ;

Bennett, Bryson D. ;

Coller, Hilary A. ;

Cross, Justin R. ;

Fantin, Valeria R. ;

Hedvat, Cyrus V. ;

Perl, Alexander E. ;

Rabinowitz, Joshua D. ;

Carroll, Martin ;

Su, Shinsan M. ;

Sharp, Kim A. ;

Levine, Ross L. ;

Thompson, Craig B. .

CANCER CELL, 2010, 17 (03) :225-234

[13] IDH1 and IDH2 Mutations in Gliomas [J].

Yan, Hai ;

Parsons, D. Williams ;

Jin, Genglin ;

McLendon, Roger ;

Rasheed, B. Ahmed ;

Yuan, Weishi ;

Kos, Ivan ;

Batinic-Haberle, Ines ;

Jones, Sian ;

Riggins, Gregory J. ;

Friedman, Henry ;

Friedman, Allan ;

Reardon, David ;

Herndon, James ;

Kinzler, Kenneth W. ;

Velculescu, Victor E. ;

Vogelstein, Bert ;

Bigner, Darell D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (08) :765-773

[14] Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α [J].

Zhao, Shimin ;

Lin, Yan ;

Xu, Wei ;

Jiang, Wenqing ;

Zha, Zhengyu ;

Wang, Pu ;

Yu, Wei ;

Li, Zhiqiang ;

Gong, Lingling ;

Peng, Yingjie ;

Ding, Jianping ;

Lei, Qunying ;

Guan, Kun-Liang ;

Xiong, Yue .

SCIENCE, 2009, 324 (5924) :261-265

← 1 2 →